Company news
PharmaCyte Biotech, Inc. news in 2021
PharmaCyte Biotech, Inc.'s news releases, calls and decks from 2021, newest first.
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
December 27, 2021
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
December 14, 2021
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
December 7, 2021
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
November 29, 2021
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
November 11, 2021
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
September 26, 2021
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
September 20, 2021
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
September 15, 2021
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 7, 2021
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
August 30, 2021
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
August 24, 2021
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
August 22, 2021
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
August 18, 2021
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
August 15, 2021
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
August 11, 2021
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
August 8, 2021
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
August 1, 2021
PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment
July 21, 2021
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
July 13, 2021
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
July 11, 2021
PharmaCyte Biotech Announces Reverse Stock Split
July 8, 2021
PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
July 7, 2021
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
June 23, 2021
PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital
June 21, 2021
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
June 17, 2021
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
June 13, 2021
PharmaCyte Biotech Successfully Completes 1 Year Stability Study
March 31, 2021
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product
January 25, 2021
Decks in 2021
- Investor Presentation (September 2021)
Investor deck · 40 slides · Sep 10, 2021